New Meds and Tech

In March 2023, the FDA extended the approval of Evinacumab (EVKEEZA©) to children 5-11 years with familial homozygous hypercholesteremia. Evinacumab had been previously approved for 12…

US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties. New Drugs and Therapeutics   On October 26, 2023, the US…

LUPRON DEPOT-PED 45 mg for 6 months Prepared and edited on behalf of the PES Drug & Therapeutics committee: Shilpa Mehta, MD, Amit Lahoti, MD, Aditi…

New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD   NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)   Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)…

New Meds and Tech from PES Drugs and Therapeutics committee Palovarotene (SohonosTM – Ipsen Pharmaceuticals Inc.) By: Ambika Ashraf, MD and Anna Ryabets-Lienhard, DO   Update:…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee iLet ® Bionic Pancreas   On May 19, 2023, the U.S. Food and Drug Administration approved the…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee Sogroya® (somapactian) Once weekly Sogroya® (somapacitan-beco, Novo Nordisk) was approved by the United States Food and Drug…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee The MiniMed™780G System The MiniMed 780G System from Medtronic was approved by the US Food and Drug…

Dexcom G7   In December 2022, the Dexcom G7 continuous glucose monitor system was cleared by the FDA for use in people age 2 and older…